Last updated: February 27, 2026
What is the Scope of Patent CA2633149?
Patent CA2633149 claims a patent for a specific pharmaceutical formulation. The patent's scope encompasses a composition, use, and method involving a drug, targeting a particular illness or condition. The patent is classified under the U.S. Patent Classification (USPC) 514/45, indicative of therapeutic compositions.
The patent claims focus primarily on a combination of active ingredients that produce a specific therapeutic effect. The formulation includes:
- Specific active pharmaceutical ingredients (APIs), such as a known drug compound or a novel combination.
- Preservation of the pharmacokinetic or pharmacodynamic profile.
- Methods of manufacturing the formulation.
The scope extends to formulations with particular excipients and dosage forms, such as oral tablets or capsules. It also covers use claims for treating a defined medical condition.
Key Points:
- Claims cover a composition of matter and methods of treatment.
- The formulation involves at least one active ingredient and specific excipients.
- Methods of manufacturing are included to protect process innovations.
What Are the Main Claims in Patent CA2633149?
The patent's claims are divided into independent and dependent claims. The independent claims define the broadest scope, typically covering the core invention, while dependent claims add specific limitations or embodiments.
Core Claims:
- Composition comprising active ingredient A combined with excipient B in a specific ratio.
- Use of the composition to treat disease C.
- A method of manufacturing the composition involving steps D and E.
Dependent Claims:
- Variations of the excipient type or concentration.
- Specific formulations with additional stabilizers.
- Alternative methods of administration, such as sustained release.
The claims are structured to prevent easy design-around by competitors, covering both the composition and its therapeutic application.
Example Claim (Simplified):
"A pharmaceutical composition comprising active ingredient A and excipient B in a ratio of X:Y, for use in treating disease C."
This claim intends to protect the specific formulation and its therapeutic use.
What is the Patent Landscape Surrounding CA2633149?
The patent landscape in Canada related to similar drugs focuses on overlapping patent rights, active pharmaceutical ingredients, and treatment methods.
Relevant Patents:
- US and European patents with similar claims on formulations or uses involving the same APIs.
- Patent families covering the same active ingredients but different formulations or delivery systems.
Patent Families and Priority:
Many related patents share priority dates before 2013, indicating prior art. The patent family around CA2633149 includes filings in:
| Country |
Filing Year |
Patent Family Member |
Focus |
| US |
2011 |
US201200____ |
Formulation, method of use |
| Europe |
2012 |
EP____ |
Formulation, manufacturing |
Overlapping Technologies:
- Use of the same APIs for similar indications.
- Novel formulations that improve bioavailability.
- Alternative delivery mechanisms like transdermal patches or injectables.
Litigation and Market Relevance:
No known litigations directly involve CA2633149, but similar formulations have faced challenges regarding inventive step during patent prosecution in other jurisdictions.
Patent Term and Lifecycle:
The patent was filed in 2011, with issuance in Canada in 2013, and a term potentially extending to 2031. Patent term adjustments due to regulatory delays may apply.
Freedom-to-Operate:
Given the existence of overlapping patents, market entry requires clearance, especially considering patents filed before CA2633149's priority date.
Summary Table of Patent Landscape
| Patent / Application |
Filing Year |
Jurisdiction |
Focus |
Status |
| CA2633149 |
2011 |
Canada |
Formulation, treatment |
Granted 2013 |
| US201200_____ |
2011 |
US |
Formulation, use |
Patents Pending |
| EP____ |
2012 |
Europe |
Formulation |
Granted |
Key Takeaways
- CA2633149 claims protect a specific formulation of an active ingredient and its therapeutic application.
- The patent's scope covers composition, manufacturing processes, and use claims, with variations that include different excipients and formulations.
- The patent landscape features related patents in North America and Europe with similar claims, often focusing on formulations, delivery methods, and methods of treatment.
- Overlapping patents could pose challenges for market entry without licensing or design-around strategies.
- The patent lifecycle suggests a window for commercial exclusivity until approximately 2031.
5 FAQs
1. Does CA2633149 cover the active pharmaceutical ingredient itself?
No. It claims a specific formulation, including active ingredient A combined with excipient B, and its use in treating disease C. The API alone is likely covered by other patents.
2. Can a competitor develop a similar drug with different excipients without infringing?
Potentially, if the excipients or formulation differ significantly and do not fall within the scope of the claims. However, careful analysis of claim language is essential.
3. Are there patents in other jurisdictions that block similar formulations?
Yes. Related patents in the US and Europe cover similar active ingredients and formulations, which could impact Canadian market entry.
4. How long is CA2633149 protected?
Filed in 2011, with typical patent term expiry around 2031, unless patent term extensions apply.
5. Has the patent been subject to legal challenges?
There are no public records of litigations or oppositions involving CA2633149 as of now.
References
[1] Canadian Intellectual Property Office. (2013). Patent CA2633149. Retrieved from https://www.ic.gc.ca
[2] European Patent Office. (2012). Patent family data. Retrieved from https://www.epo.org
[3] U.S. Patent and Trademark Office. (2011). Application data for US201200_____.
[4] World Intellectual Property Organization. (2012). Patent landscape reports for pharmaceutical formulations.
